News

GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, announced a collaboration with Arvinas, Inc. a…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian…
Read More...

OPKO Health, Inc. announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for…
Read More...

Aztiq Pharma Partners ("Aztiq"), a private equity company led by Alvogen Founder and Chairman Róbert Wessman, and Innobic (Asia) Company Limited ("Innobic") have completed the…
Read More...

InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid…
Read More...

Citius Pharmaceuticals, Inc. a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, announced that it has selected Biorasi, LLC…
Read More...

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, announced a five-year partnership to…
Read More...

ADVANZ PHARMA Corp. Limited, a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, has signed an agreement with Intercept…
Read More...

Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain Orion Corporation has entered into an agreement with Chinese…
Read More...

Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE…
Read More...

Novartis announced the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GvHD who have inadequate…
Read More...

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI…
Read More...

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that the last patient has completed the treatment period in its Phase 2 proof of…
Read More...

Stevanato Group S.p.A. a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an…
Read More...

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that…
Read More...

CYTENA, a BICO group company and a leading provider of high-precision instruments for handling biological cells, has entered a collaboration agreement with ExcellGene SA, a leading…
Read More...

Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain to expand the authorization of Nuvaxovid (NVX-CoV2373)…
Read More...

Novartis announced that the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
Read More...

Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, announced a strategic collaboration with…
Read More...

Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced that the U.S. Food…
Read More...